Cargando…
阿法替尼一线治疗5例晚期肺腺癌患者的不良反应分析及相关文献回顾
BACKGROUND AND OBJECTIVE: Afatinib is an irreversible ErbB-family blocker with a clinical activity in non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations. The aim of this study is to assess the safety of afatinib in patients with advanced lung adenocarcinoma. METHODS: P...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000023/ https://www.ncbi.nlm.nih.gov/pubmed/24758910 http://dx.doi.org/10.3779/j.issn.1009-3419.2014.04.09 |
Ejemplares similares
-
盐酸埃克替尼一线治疗晚期肺腺癌的临床疗效观察
Publicado: (2013) -
厄洛替尼100 mg/天治疗化疗后进展的晚期肺腺癌的临床研究
Publicado: (2011) -
慢性髓性白血病患者达沙替尼相关的肺部不良反应分析
Publicado: (2020) -
晚期EGFR突变型非小细胞肺癌患者接受吉非替尼或厄洛替尼治疗的成本效益分析
Publicado: (2013) -
凡德他尼治疗5例晚期复治肺腺癌患者的临床观察及相关文献回顾
Publicado: (2012)